Kadimastem Ltd (KMSTF)
USD 6.4
(0.0%)
USD 6.4
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.62 Million USD | 57.74% |
| 2022 | -5.7 Million USD | 21.06% |
| 2021 | -7.22 Million USD | -25.61% |
| 2020 | -5.75 Million USD | 15.92% |
| 2019 | -6.84 Million USD | 2.43% |
| 2018 | -7.01 Million ILS | -20.67% |
| 2017 | -20.93 Million ILS | -20.15% |
| 2016 | -18.61 Million ILS | 64.86% |
| 2015 | -14.64 Million ILS | 11.5% |
| 2014 | -14.84 Million ILS | 7.76% |
| 2013 | -14.49 Million ILS | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | -1.43 Million USD | 0.0% |
| 2023 Q4 | -944.93 Thousand USD | 0.0% |
| 2023 FY | - USD | 57.74% |
| 2022 FY | - USD | 21.06% |
| 2022 Q2 | -3.18 Million USD | 0.0% |
| 2022 Q4 | -2.53 Million USD | 0.0% |
| 2021 Q2 | -3.67 Million USD | 0.0% |
| 2021 FY | - USD | -25.61% |
| 2021 Q4 | -3.36 Million USD | 0.0% |
| 2020 Q2 | -3 Million ILS | 46.48% |
| 2020 Q1 | -5.62 Million ILS | -65.04% |
| 2020 Q4 | -2.5 Million USD | 0.0% |
| 2020 FY | - USD | 15.92% |
| 2019 FY | - USD | 2.43% |
| 2019 Q4 | -3.4 Million USD | 0.0% |
| 2019 Q2 | -3.32 Million USD | 0.0% |
| 2018 FY | - ILS | -20.67% |
| 2017 FY | - ILS | -20.15% |
| 2016 FY | - ILS | 64.86% |
| 2015 FY | - ILS | 11.5% |
| 2014 FY | - ILS | 7.76% |
| 2013 FY | - ILS | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 96.306% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 55.736% |
| SQZ Biotechnologies Company | -64.14 Million USD | 95.908% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 84.891% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 102.791% |
| Mesoblast Limited | -62.38 Million USD | 95.794% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -70.853% |
| Genus plc | 73.7 Million USD | 103.561% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 60.306% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 26.011% |
| Marizyme, Inc. | -34.28 Million USD | 92.345% |
| ContraFect Corporation | -64.99 Million USD | 95.962% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 70.082% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 42.018% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -87.214% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 0.759% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -12.934% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -406.592% |
| Accustem Sciences Inc. | -3.74 Million USD | 29.95% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 94.558% |
| EV Biologics, Inc. | -1.26 Million USD | -107.112% |
| Q BioMed Inc. | -617.62 Thousand USD | -324.913% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 173.471% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -314.984% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -14.878% |
| Biomind Labs Inc. | -1.03 Million USD | -153.674% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 126.571% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 63.353% |
| Skye Bioscience, Inc. | -13.54 Million USD | 80.628% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -76.439% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -10397.524% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 32.437% |
| IMV Inc. | -35.52 Million USD | 92.612% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 83.463% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -4.893% |
| GB Sciences, Inc. | -1.41 Million USD | -84.831% |
| Alpha Cognition Inc. | -9.7 Million USD | 72.96% |
| HST Global, Inc. | -5303.00 USD | -49388.61% |
| CSL Limited | 4.78 Billion USD | 100.055% |
| Halberd Corporation | -74.27 Thousand USD | -3433.14% |
| Enzolytics Inc. | -2.12 Million USD | -23.673% |
| Resverlogix Corp. | -11.74 Million USD | 77.65% |
| Affymax, Inc. | -14.29 Million USD | 81.641% |
| SYBLEU INC | -141.57 Thousand USD | -1753.756% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 14.32% |
| argenx SE | -216.02 Million USD | 98.785% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 95.258% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 315.643% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -75.086% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 792.734% |
| AVAX Technologies, Inc. | -6.11 Million USD | 57.066% |
| Zenith Capital Corp. | -8.6 Million USD | 69.505% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.945% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -14964.468% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -7.273% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1390.919% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 93.379% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 9.264% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -150.822% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 39130.057% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -49.965% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -36.622% |
| BioStem Technologies, Inc. | -7.55 Million USD | 65.257% |
| ONE Bio Corp. | 13.61 Million USD | 119.278% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1349.23% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -27.583% |
| Agentix Corp. | -1.37 Million USD | -91.315% |
| LadRx Corporation | 412.28 Thousand USD | 736.548% |
| Cell Source, Inc. | -4.27 Million USD | 38.575% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -614.66% |
| Regen BioPharma, Inc. | 1.46 Million USD | 279.022% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -180.099% |
| NovAccess Global Inc. | -1.03 Million USD | -153.613% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 129.641% |
| Itoco Inc. | -1.86 Million USD | -40.417% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -591.318% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -135.16% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -997.379% |
| CytoDyn Inc. | -18.02 Million USD | 85.444% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -3220.782% |
| Mobile Lads Corp. | -2.24 Million USD | -17.099% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -21360.307% |
| Qrons Inc. | -40.08 Thousand USD | -6447.693% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -440.354% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 597.576% |
| Rebus Holdings, Inc. | -951 Thousand USD | -175.96% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -147.115% |
| International Stem Cell Corporation | 202 Thousand USD | 1399.199% |
| Bioxytran, Inc. | -3.82 Million USD | 31.302% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4885.526% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -6.598% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 92.683% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -5731.958% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 4.15% |
| Neutra Corp. | -181.24 Thousand USD | -1347.958% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 86.982% |
| PureTech Health plc | -11.62 Million USD | 77.429% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 86.981% |
| IXICO plc | -707 Thousand USD | -271.2% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 65.851% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 94.572% |
| CSL Limited | 4.73 Billion USD | 100.055% |
| Cellectis S.A. | -92.63 Million USD | 97.167% |